What Is SS-31 (Elamipretide)? An Introduction to the Mitochondria-Targeting Peptide
Among the most compelling developments in peptide research over the past decade, SS-31—also known by its clinical name elamipretide—has emerged as a uniquely promising compound. Unlike most research peptides that target hormonal pathways or receptor systems, SS-31 works at the most fundamental level of cellular biology: the mitochondria. This tetrapeptide (a chain of just four amino acids: D-Arg-Dmt-Lys-Phe-NH₂) has attracted serious scientific attention for its ability to stabilize mitochondrial membranes and restore cellular energy production.
In September 2025, SS-31 (elamipretide) received FDA approval for Barth syndrome, a rare mitochondrial disease affecting the heart and skeletal muscles. This milestone validated years of preclinical and clinical research and has intensified interest in the peptide's broader potential applications—from heart failure to age-related metabolic decline. This article explores the science behind SS-31, what the research currently shows, and why it has become one of the most-watched peptides in the research community.
The Mechanism of Action: How SS-31 Targets Mitochondria
To understand why SS-31 is so significant, it helps to understand the role of mitochondria in cellular health. Mitochondria are the energy-producing organelles found in virtually every cell of the body. They generate adenosine triphosphate (ATP)—the primary currency of cellular energy—through a process called oxidative phosphorylation. When mitochondria become dysfunctional, cells lose their ability to produce adequate energy, leading to a cascade of problems including oxidative stress, inflammation, and cell death.
SS-31 works through a highly specific mechanism:
- Cardiolipin binding: SS-31 selectively concentrates in the inner mitochondrial membrane, where it binds to a phospholipid called cardiolipin. Cardiolipin is essential for the structural integrity of the inner membrane and for the function of the electron transport chain (ETC)—the machinery that produces ATP.
- Electron transport chain stabilization: By binding to cardiolipin, SS-31 helps maintain the proper organization of ETC complexes, particularly Complex I and Complex III. This stabilization improves electron flow and reduces the "leakage" of electrons that generates harmful reactive oxygen species (ROS).
- Reduction of oxidative stress: By minimizing electron leakage, SS-31 dramatically reduces the production of mitochondrial ROS—the primary driver of oxidative damage in aging and disease.
- Restoration of membrane potential: SS-31 helps restore the electrochemical gradient across the inner mitochondrial membrane, which is essential for efficient ATP synthesis.
This mechanism is fundamentally different from antioxidants like vitamin C or E, which simply neutralize ROS after they are produced. SS-31 addresses the source of oxidative stress by improving mitochondrial efficiency itself. Researchers describe this as a "upstream" intervention—fixing the problem at its root rather than managing its consequences.
SS-31 and Barth Syndrome: The FDA Approval Story
Barth syndrome is a rare X-linked genetic disorder caused by mutations in the tafazzin gene, which is responsible for the remodeling of cardiolipin. Without functional tafazzin, cardiolipin becomes abnormal, mitochondria malfunction, and patients—almost exclusively young males—develop severe cardiomyopathy, skeletal muscle weakness, and growth delays. Many do not survive to adulthood without intervention.
Clinical trials of elamipretide in Barth syndrome patients demonstrated meaningful improvements in:
- Exercise tolerance (measured by the 6-minute walk test)
- Skeletal muscle strength
- Cardiac function (left ventricular ejection fraction)
- Patient-reported quality of life
The FDA's approval of elamipretide for Barth syndrome in September 2025 under the brand name Stealth BioTherapeutics represented a landmark moment—not just for Barth syndrome patients, but for the entire field of mitochondrial medicine. It provided the first clinical proof-of-concept that a peptide targeting cardiolipin could produce meaningful therapeutic outcomes in humans with mitochondrial dysfunction.
Beyond Barth Syndrome: Emerging Research Applications
Heart Failure with Preserved Ejection Fraction (HFpEF)
One of the most active areas of SS-31 research is heart failure with preserved ejection fraction (HFpEF)—a form of heart failure where the heart muscle contracts normally but the ventricles are stiff and don't fill properly. HFpEF accounts for roughly half of all heart failure cases and has historically been difficult to treat. Mitochondrial dysfunction is now recognized as a central feature of HFpEF pathophysiology.
Phase 3 clinical trials of elamipretide in HFpEF patients are ongoing as of 2026. Early data from Phase 2 trials showed improvements in exercise capacity and cardiac energetics. Researchers are particularly interested in whether SS-31 can address the underlying mitochondrial deficits that drive HFpEF, rather than simply managing symptoms.
Ischemia-Reperfusion Injury
When blood flow is restored to tissue after a period of ischemia (such as during a heart attack or stroke), a paradoxical burst of oxidative damage occurs—known as ischemia-reperfusion (I/R) injury. This injury is driven largely by mitochondrial ROS production during reperfusion. Preclinical studies have shown that SS-31 administered before or during reperfusion significantly reduces infarct size and preserves cardiac function in animal models. This has generated interest in SS-31 as a potential cardioprotective agent in surgical and emergency medicine contexts.
Age-Related Mitochondrial Decline
One of the hallmarks of biological aging is the progressive decline in mitochondrial function. As we age, mitochondria accumulate damage, produce less ATP, and generate more ROS—contributing to the fatigue, muscle loss, and cognitive decline associated with aging. Research in aged animal models has shown that SS-31 treatment can:
- Restore mitochondrial membrane potential to levels seen in younger animals
- Improve skeletal muscle function and exercise capacity
- Reduce markers of oxidative stress in multiple tissues
- Improve kidney function in models of age-related renal decline
These findings have positioned SS-31 as a potential geroscience compound—one that targets the fundamental biology of aging rather than individual age-related diseases.
Kidney Disease and Renal Protection
The kidneys are among the most metabolically active organs in the body and are highly dependent on mitochondrial function. Preclinical research has demonstrated that SS-31 can protect against acute kidney injury (AKI) in models of ischemia, nephrotoxicity, and sepsis. Studies in models of chronic kidney disease (CKD) have also shown reductions in fibrosis and preservation of renal function. Clinical trials exploring SS-31 for renal protection are in early stages.
Neurodegenerative Disease Research
Mitochondrial dysfunction is increasingly recognized as a key driver of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS. In animal models of these conditions, SS-31 has demonstrated the ability to reduce neuronal oxidative stress, preserve synaptic function, and slow disease progression. While human clinical data in neurodegeneration remains limited, the preclinical evidence has generated significant interest among researchers in this space.
SS-31 vs. Other Mitochondria-Targeting Compounds
SS-31 is not the only compound that researchers have explored for mitochondrial support, but it has several characteristics that distinguish it from alternatives:
- vs. MitoQ and SkQ1: These are mitochondria-targeted antioxidants that use a lipophilic cation to concentrate in mitochondria. Unlike SS-31, they do not bind cardiolipin directly and may have pro-oxidant effects at high concentrations. SS-31's cardiolipin-binding mechanism is considered more targeted and mechanistically specific.
- vs. NAD+ precursors (NMN, NR): NAD+ precursors support mitochondrial function by replenishing NAD+ levels, which are required for the electron transport chain. SS-31 and NAD+ precursors work through complementary mechanisms and may have synergistic potential, though this has not been formally studied in humans.
- vs. Urolithin A: Urolithin A promotes mitophagy—the clearance of damaged mitochondria. SS-31 focuses on preserving and restoring the function of existing mitochondria. Again, these represent complementary rather than competing approaches.
Dosing Considerations in Research Contexts
It is important to emphasize that SS-31 (elamipretide) is currently approved by the FDA only for Barth syndrome, and its use in other contexts remains investigational. The following information is provided strictly for educational and research purposes. Anyone considering the use of any peptide compound should consult with a qualified healthcare professional.
In clinical trials, elamipretide has been administered primarily via subcutaneous injection. The approved dosing for Barth syndrome involves daily subcutaneous injections. In research settings, the peptide is typically reconstituted using bacteriostatic water and stored refrigerated to maintain stability.
Key considerations that researchers have noted include:
- Stability: Like most peptides, SS-31 is sensitive to heat, light, and repeated freeze-thaw cycles. Proper cold-chain storage is essential for maintaining peptide integrity.
- Injection site reactions: The most commonly reported adverse effect in clinical trials has been mild injection site reactions (redness, swelling), which are typical for subcutaneous peptide administration.
- Half-life: SS-31 has a relatively short plasma half-life, which is why daily dosing has been used in most clinical protocols.
- Purity and sourcing: As with all research peptides, the quality and purity of the compound is critical. Researchers should source peptides only from reputable suppliers with verifiable third-party testing. Progressing (cpwt.shop) is one such supplier, offering research-grade peptides with documented quality standards for legitimate research applications.
Potential Risks and Side Effects: What the Research Shows
SS-31's clinical safety profile, as established through trials in Barth syndrome and other conditions, has been generally favorable. The most commonly reported adverse effects include:
- Injection site reactions: Mild erythema (redness), pain, or swelling at the injection site. These are typically transient and resolve without intervention.
- Fatigue: Some participants in clinical trials reported mild fatigue, though this was difficult to distinguish from disease-related fatigue in the study populations.
- Headache: Reported in a subset of trial participants.
Serious adverse events attributable to elamipretide have been rare in clinical trials. However, it is important to note that long-term safety data in healthy individuals or in conditions beyond those studied in trials is not yet available. The research community continues to monitor for any emerging safety signals as clinical use expands.
As with any investigational compound, individuals with pre-existing medical conditions, those taking medications, pregnant or breastfeeding individuals, and minors should not use SS-31 outside of a supervised clinical research context. This article does not constitute medical advice, and the information presented here is intended solely for educational purposes.
The Broader Significance of SS-31 for Mitochondrial Medicine
The story of SS-31 is, in many ways, the story of a paradigm shift in how researchers think about disease and aging. For decades, the dominant model of disease focused on specific molecular targets—a receptor here, an enzyme there. SS-31 represents a different approach: targeting the fundamental cellular machinery that underlies a wide range of conditions.
Mitochondrial dysfunction is now recognized as a contributing factor in conditions as diverse as heart failure, kidney disease, neurodegeneration, metabolic syndrome, and aging itself. A compound that can meaningfully restore mitochondrial function could, in theory, have broad therapeutic relevance across all of these domains. This is why SS-31 has attracted attention not just from cardiologists and rare disease specialists, but from geroscientists, neurologists, and metabolic researchers.
The FDA approval for Barth syndrome was a critical proof-of-concept. It demonstrated that the cardiolipin-targeting mechanism works in humans, that the peptide is safe enough for chronic use, and that mitochondrial medicine is a viable therapeutic strategy. The ongoing Phase 3 trials in HFpEF and other conditions will be closely watched as potential indicators of how broadly this approach can be applied.
What to Watch: SS-31 Research in 2026 and Beyond
Several key developments in SS-31 research are expected to unfold over the coming years:
- HFpEF Phase 3 trial results: These results will be pivotal in determining whether elamipretide can achieve regulatory approval for a much larger patient population than Barth syndrome.
- Aging and longevity studies: Researchers at several academic institutions are conducting studies examining SS-31's effects on biomarkers of aging in older adults, including mitochondrial function, physical performance, and inflammatory markers.
- Combination approaches: Preclinical research is exploring whether SS-31 combined with other mitochondria-supporting compounds (such as NAD+ precursors or urolithin A) produces additive or synergistic effects.
- Delivery system innovation: Like many peptides, SS-31 currently requires injection. Research into oral or transdermal delivery systems could significantly expand its accessibility if successful.
- Biomarker development: Identifying reliable biomarkers of mitochondrial function that can be measured in clinical settings would help researchers better assess SS-31's effects and identify which patients are most likely to benefit.
Conclusion: SS-31 as a Window Into the Future of Peptide Research
SS-31 (elamipretide) represents one of the most scientifically grounded and clinically advanced peptides in the current research landscape. Its FDA approval for Barth syndrome has moved it from the realm of preclinical curiosity to validated therapeutic agent, and its ongoing clinical development across multiple conditions reflects the breadth of its potential applications.
For researchers and educators in the peptide science space, SS-31 offers a compelling case study in how a deep understanding of cellular biology—in this case, the role of cardiolipin in mitochondrial function—can lead to the development of highly targeted, mechanistically rational therapeutic compounds. As the science continues to evolve, SS-31 will likely remain at the forefront of discussions about mitochondrial medicine, aging biology, and the future of peptide-based therapeutics.
As always, anyone interested in peptide research should approach the field with scientific rigor, consult qualified healthcare professionals before considering any personal use, and rely on reputable, well-documented sources for both information and research materials.